Bristol Myers Squibb has ended its partnership with cell therapy manufacturing startup Cellares, saying its Cell Shuttle commercial manufacturing technology did not meet expectations. Cellares said it has been defending its approach, following BMS’s withdrawal and related claims about performance. The contract termination triggers restructuring at Cellares and introduces additional uncertainty into the supply-chain planning for cell therapy developers relying on external manufacturing platforms. In parallel, the incident highlights a broader operational risk in autologous and other advanced cell therapy workflows: manufacturing readiness is increasingly treated as a gating factor for partnerships and clinical timelines. For investors and pipeline teams, the fallout underscores the importance of validation criteria, tech-transfer maturity, and batch consistency in scaling next-generation manufacturing methods.